Blood test study for decision-making in cetuximab-treated colon cancer
Part of Cancer, Digestive system clinical trials.
This trial studies how a blood test (ctDNA, a tumor DNA signal) can help guide next steps for people with metastatic colorectal cancer whose disease got worse after a first treatment that included cetuximab. If the blood test is informative, it may help doctors make better treatment decisions after first-line failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have colorectal adenocarcinoma that is metastatic or cannot be fully removed with surgery.
- Your tumor tests show RAS and BRAF are “wild-type,” and you were on first-line treatment that included cetuximab, with scans showing progression.
- Your general health is good enough (ECOG score 0–2) and you’re expected to live more than 3 months.
- Your blood counts and organs must be strong enough (for example: neutrophils ≥1.5, platelets ≥100, hemoglobin ≥90; liver, kidney, and heart function within limits).
- You have at least one measurable cancer spot on imaging and you can sign the informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding cetuximab to irinotecan can control metastatic colorectal cancer that has returned or worsened after standard treatments. It targets people whose tumor is left-sided and shows “wild-type” RAS and BRAF genes on blood testing after prior therapy.
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This trial compares two different chemotherapy combinations, both including a targeted therapy called cetuximab, as a first treatment for people with a specific type of advanced left-sided colon cancer that cannot be surgically removed. The goal is to find out which combination works better.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.